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Heart failure in a woman with SLE, anti-phospholipid
syndrome and Fabry’s disease
A Nandagudi1, EC Jury2, D Alonzi3, TD Butters3, S Hughes4 and DA Isenberg1,2
1Department of Rheumatology, University College Hospital, UK; 2Centre for Rheumatology Research, Department of Medicine,
University College London, UK; 3Oxford Glycobiology Institute, Department of Biochemistry, University of Oxford,
UK; and 4Department of Histopathology, University College Hospital, UK
We describe a female patient with systemic lupus erythematosus (SLE) also diagnosed with
Fabry’s disease and anti-phospholipid antibody syndrome (APS). SLE and Fabry’s disease
are both systemic diseases with variable clinical presentations. Recent studies have shown a
relatively high incidence of late onset Fabry’s disease in female heterozygous individuals,
suggesting that this condition could be under-diagnosed. We discuss a possible association
between SLE and Fabry’s disease and consider the role of lipid abnormalities in the patho-
genesis of SLE. Lupus (2013) 22, 1070–1076.
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Introduction
This case describes a female patient with systemic
lupus erythematosus (SLE) and antiphospholipid
antibody syndrome (APS). The patient went on to
develop atypical symptoms of heart disease and was
diagnosed with the lysosomal storage disease,
Fabry’s disease (FD), which is characterized by the
accumulation of lipids in organs and tissues. SLE
and FD are both systemic diseases with variable clin-
ical presentations. Recent studies have shown a rela-
tively high incidence of late onset FD in female
heterozygous individuals, suggesting that this condi-
tion could be under-diagnosed. Interestingly, the pat-
tern of organ involvement in patients with SLE and
FD can be similar and this case highlights similarities
in disease pathogenesis between the two conditions.
We discuss a possible association between SLE and
FD and consider the role of lipid abnormalities in the
pathogenesis of SLE.
Case presentation
A 38-year-old Caucasian woman presented with
exertional chest pain with shortness of breath.
History of present illness
The patient was diagnosed with SLE in 1987 with
an unusual presentation including arthralgia and
loose stools. At diagnosis her autoimmune proﬁle
was diﬀuse pattern antinuclear antibody 1/640,
positive anti-double-stranded (ds)DNA, negative
extractable nuclear antigens (ENA, including anti-
Ro) and low complement C3 and C4.
Antiphospholipid antibodies (aPL) were negative
at diagnosis but became positive in 1996. She had
a history of photosensitivity, malar rash, occasional
mouth ulcers, increased sweating and joint pain
(knees, hands and spine). She had no constitutional
symptoms or history suggestive of active infection
and no neurological symptoms, cataract, tinnitus,
hearing loss or angiokeratoma. Her father died at
age 65 with congestive cardiac failure and her
mother was alive at age 67 having had a subarach-
noid haemorrhage but she had no other cardiovas-
cular risk factors (non-smoker with normal serum
cholesterol). The patient had a history of secondary
Sjo¨gren’s syndrome, sensory epilepsy and migraine.
Treatment included hydroxycholoroquine
(1987–2007) 400mg/day, azathioprine (from 1990)
100mg and prednisolone 5mg. She was also on
sodium valproate, cyclizine, amitriptyline, losartan
and ibuprofen and had been reviewed routinely by
a cardiologist in 1988 with no evidence of heart
disease and a normal electrocardiogram (ECG).
In a second review in 1999 the echocardiogram
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demonstrated normal posterior and inter-ventricu-
lar septum wall thickness of 0.9 cms. The valves
were normal and the function was good at that
stage.
In April 2002 she presented with shortness of
breath and exertional chest pain when walking
upstairs or on inclines. The pain was central and
radiated to the left arm. She also complained of
palpitations, describing a ‘pounding sensation’
which improved with losartan. She gave no history
of syncope but occasionally complained of presyn-
cope when standing up rapidly, and tiredness. In
June 2002 she had distinct changes in her exercise
capacity and was moderately hypertensive; she was
referred to a cardiologist.
Physical examination
She was afebrile and moderately hypertensive
(140/70), pulse was 90, regular and venous pressure
was elevated. Other vital signs were stable. She
weighed 80 kg and her height was 167.2 cm. There
was peripheral oedema but no clubbing. She had a
butterﬂy facial rash but no angiokeratoma. Joint
exam was normal with no evidence of synovitis.
The reﬂexes were normal and symmetrical and
there was no sensory deﬁcit. There was 2/6 ejection
systolic murmur at the left sternal edge and basal
crepitations on chest examination. There was no
hepatosplenomegaly.
Investigations
Her routine full blood count, urea, electrolytes,
liver functions, thyroid function and urinary pro-
tein creatinine ratio were normal. ECG showed
marked QRS changes with hypertrophy, mild
QRS broadening and widespread anterolateral ST
segment abnormalities. There was sinus rhythm
with voltage criteria for left ventricle hypertrophy
and normal PR interval. Echocardiogram demon-
strated a small left ventricular (LV) cavity with con-
centric LV hypertrophy with a maximal thickness
of 1.7 cm. She had complete LV obliteration on
apical view but there was no signiﬁcant outﬂow
gradient. She had evidence of impaired relaxation
on the transmitral Doppler. There was also evi-
dence of moderate right ventricular hypertrophy.
The valves were thin, mobile with no lesions and
no pericardial eﬀusion. Coronary angiogram
demonstrated normal coronary arteries.
Diagnosis
Echocardiograph showed cardiomyopathy (CM)
changes (concentric hypertrophy with posterior
wall and interventricular septum thickness of 2 cm
which was absent in 1999 with the thickness being
0.9 cm). The heart biopsy showed no evidence of
amyloid. The sarcoplasmic vacuolation and myoﬁ-
brillary loss of myocytes seen in the heart biopsy
was due to glycosphingolipid deposition (Figure 1(a))
and massive deposition of electron-dense glyco-
sphingolipid in the form of myelin ﬁgures in the
myocyte sarcoplasm (Figure 1(b)). A similar
appearance can be observed in hydroxychloro-
quine-associated CM (hydroxycloroquine inhibits
the function of lysosomal enzymes1). However,
when myelin ﬁgures are present in large numbers,
FD should be considered and conﬁrmed by more
speciﬁc investigations.
FD is an X-linked deﬁciency of the enzyme a-
galactosidase A (GLA), resulting in accumulation
of the glycosphingolipid globotriaosylceramide
(Gb3) in organs and tissues. GLA activity was
low in this patient at 39 nmol/hr/mg protein
(normal range 33–134), and genetic testing in
August 2003 showed a rare P343L mutation in
the GLA enzyme, conﬁrming the diagnosis.
Figure 1 Heart biopsy from the systemic lupus erythematosus (SLE) patient showing pathology consistent with Fabry’s disease.
(a) Haematoxylin and eosin-stained light micrograph section showing sarcoplasmic vacuolation and myofibrillary loss of myocytes.
Magnification 200 and (b) Electron micrograph showing electron-dense glycosphingolipid in the form of myelin figures in the
myocyte sarcoplasm.
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Treatment and subsequent course
The patient was treated with enzyme-replacement
therapy (ERT), agalsidase beta (Fabrazyme),
aspirin and diltiazem. Hydroxychloroquine was
stopped in November 2007 when a maculopathy
was suspected and she has been reviewed regularly
since by the ophthalmologists.
In 2008 her echocardiogram showed mild LV
dilatation with hypokinesis of the anterior and
inferior septum (ejection fraction 50%, LV end
diastolic diameter (LVEDD) 53mm, LV end-sys-
tolic diameters (LVESD) 39mm, left atrium
34mm, septum 8mm). Tissue Doppler velocities
were reduced at the mitral valve annulus and
transmitral inﬂow conﬁrmed mild diastolic dys-
function. Right heart size and function was
normal and there was no relevant valvular abnor-
mality. There was a thin organized layer of peri-
cardial ﬁbrin with a small chronic pericardial
eﬀusion. The cardiac magnetic resonance imaging
(MRI) showed normal myocardial wall thickness
with an ejection fraction of 35%. There was exten-
sive late gadolinium enhancement aﬀecting 50%
of the myocardium. It was mainly mid-myocardial
and in some areas transmural. There was a small
pericardial eﬀusion.
She suﬀered a myocardial infarction (MI) with a
distal anterior descending artery thrombus in June
2009. Her blood tests showed increased IgM aPL
32 mplu/ml (normal range (nr) 0–9) and raised IgM
anti-b2 glycoprotein I (b2GPI) antibody 111 U/ml
(nr¼ 0–12). She was treated with atorvastatin
(80mg/day), aspirin and clopidogrel, which was
then changed to warfarin (international normalized
ratio (INR) 3–4) following discussions with haema-
tologists and rheumatologists. An unstable INR on
warfarin treatment, probably linked to variations in
her ibuprofen and ﬂuconazole, led to the replace-
ment of warfarin with dalteparin 15,000 units sub-
cutaneously (sc)/day.
In September 2011 she suﬀered a cerebrovascu-
lar accident aﬀecting the right middle cerebral
artery whilst on dalteparin. She was started on
clopidogrel temporarily and then the dalteparin
dose was gradually increased to 8500 units twice
daily. Her lupus disease activity remains relatively
inactive clinically although aPL, anti-b2 GPI anti-
bodies and lupus anticoagulant continue to be
positive. Her dsDNA antibody remained positive
(between 160 and 200 IU/ml, normal range 50)
and complement C3 level varied between 0.80 and
0.96 g/l (normal range 0.9–1.80). Her liver and
kidney function have remained stable throughout
the course.
Discussion
Differential diagnosis
The clinical presentation could have been due to
SLE-related heart disease, APS or atherosclerosis
and coronary artery disease (CAD). Rarer causes
of heart failure include infection, inﬁltrative
lesions, arrhythmias, drugs and toxins. The cor-
onary angiogram was normal and there was no
evidence of hypokinesia or akinesia on echocar-
diogram. However, the echocardiogram did
reveal increased ventricle thickness suggestive of
an inﬁltrative process such as amyloidosis or a
storage disease
SLE-related heart disease
Cardiac involvement in lupus is one of the major
causes of morbidity and mortality with SLE. It
can involve all three layers of the heart – pericar-
dium, myocardium and endocardium. Clinical
(symptomatic) pericarditis is seen in approxi-
mately 25% of SLE patients during the course
of their disease; however, asymptomatic pericar-
dial eﬀusion is more common and is usually
detected on echocardiogram. It occurs more fre-
quently at SLE onset or during relapse, although
it can occur at any time of the disease.2 Episodes
can be isolated or recurrent3 and complications
include cardiac tamponade, constrictive pericardi-
tis and purulent pericarditis.
Myocarditis is uncommon in SLE, occurring in
<10% of patients although subclinical disease is
more frequent.4 Clinical features include dys-
pnoea, tachycardia, arrhythmias which can pro-
gress to ventricular dysfunction, dilated CM and
heart failure. There are no typical ﬁndings on
ECG, and cardiac enzymes may be normal.
Large echocardiogram series have found frequen-
cies of global hypokinesis between 5% and 20%.
However, segmental areas of hypokinesis can also
be indicative of the disease.5 Magnetic resonance
has proved useful in diagnosing myocardial
involvement, even at the preclinical stage.6
However, endomyocardial biopsy remains the
investigation of choice.
The notion that lupus myocarditis is an immune
complex-mediated disease is supported by immuno-
ﬂuorescence studies demonstrating ﬁne granular
immune complex and complement deposition in
the walls and perivascular tissues of myocardial
blood vessels. Some reports demonstrate an associ-
ation between anti-SSA/Ro antibodies and
myocarditis.7
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Atherosclerosis and CAD
The prevalence of CAD ranges from 6% to 10% in
SLE patients and the risk of developing any CAD is
four to eight times higher than in control sub-
jects.8–11 In young women with SLE, the risk of
MI is increased up to 50-fold.12 Traditional risk
factors (hypertension, hyperlipidaemia, smoking,
obesity, diabetes mellitus), non-traditional risk fac-
tors (e.g. autoimmune inﬂammation) and cortico-
steroids increase the risk of CAD.
Heart involvement in APS
Heart valve lesions (vegetation, valve thickening
and dysfunction) are frequently reported in patients
with APS with and without SLE13 and in those with
aPL alone.14 Libman-Sacks endocarditis is a fea-
ture of APS. SLE and APS have similar valve
abnormalities, varying from minimal thickening
and/or vegetations to severe valve distortion and
dysfunction. Hojnik et al.14 reviewed echocardio-
graphic studies of primary APS patients and
reported 32%–38% prevalence of valve lesions
most frequently involving left-sided valves (mitral
more common than aortic), whereas Libman-Sacks
commonly involves the tricuspid valve. Turiel
et al.15 demonstrated valve abnormalities in 82%
of primary APS patients and mitral valve thicken-
ing in 63%, using trans-oesophageal echocardiog-
raphy (TEE). Erdogan et al.16 demonstrated
cardiac involvement in 84% of primary APS
patients and mitral regurgitation in 77.4%.
Valvular disease is mostly mild and asymptomatic;
only rarely (4%–6%) patients develop valve disease
severe enough to require surgical treatment.
Atherosclerosis and CAD in APS
APS patients suﬀer from an increased rate of cardio-
vascular accidents: It is the presenting manifestation
in 2.8% of patients and up to 5.5% of APS patients
suﬀer an MI during the course of their disease.13
Correlation between serum levels of aPL and anti-
b2GPI antibodies and the incidence and severity of
acute coronary syndrome,MI and stroke was shown
byVeres andothers.17Lupus anticoagulant and anti-
b2GPI antibodies are the risk factors for MI in the
assessment of SLE patient cohorts.18,19
Antimalarial (hydroxychloroquine/chloroquine)-
induced CM
According to case reports, clinical heart failure and
restrictive CM are extremely rare but potentially
life-threatening complications associated with
long-term treatment with chloroquine or
hydroxychloroquine.20–22 Other cardiac complica-
tions include myocardial thickening, cardiac insuf-
ﬁciency and conduction disorders.23 The interval
between treatment commencement and develop-
ment of cardiac complications ranges from seven
months to 25 years and the total cumulative doses
ranges from 292 g to 4380 g for chloroquine.24,25
A ﬁnding of restrictive physiology on two-
dimensional echocardiogram should prompt the
clinician to consider various aetiologies and inves-
tigate accordingly. The pathologic ﬁndings asso-
ciated with antimalarial cardiotoxicity are similar
to FD and secondary amyloidosis.24,26–28 Cardiac
biopsy with ﬁndings such as vacuolar myopathy,
myeloid bodies and curvilinear bodies can prove
helpful in cases with new onset heart failure.
Clinical resolution and signiﬁcant regression of dia-
stolic dysfunction are demonstrated with discon-
tinuation of chloroquine.
FD
FD is an X-linked deﬁciency of the lysosomal
enzyme GLA resulting in the accumulation of the
glycosphingolipid Gb3 in organs and tissues.
Accumulation of Gb3 leads to progressive organ
failure and premature death although the precise
pathogenic mechanisms leading to clinical symp-
toms are not completely understood.29 Typical
manifestations include angiokeratoma, sweating
disturbances, neuropathic pain, hearing impair-
ment as well as heart, kidney and central nervous
system involvement.30 Clinical onset in homozy-
gous males (with very low levels of GLA activity)
is severe occurring in childhood; however, hetero-
zygous females (with intermediate GLA enzyme
activity) have late onset disease or may be asymp-
tomatic. Incidence of classic onset disease is rare
(one in 37,000); however, recent neonatal screening
studies show that late onset incidence is higher than
expected (one in 3100 live births), indicating that
the true prevalence of FD is underestimated.31
Furthermore, it has been suggested that patients
with renal, cerebral and cardiac insuﬃciency of
unknown cause might have FD.32 Interestingly,
the pattern of organ involvement in patients with
SLE and FD can be similar.33
The coexistence of FD and autoimmunity
including SLE and rheumatoid arthritis has been
described previously.33–36 Patients have presented
with diﬀerent symptoms (including eye, renal and
cardiac involvement) consistent with the heteroge-
neous nature of FD. Here we describe a patient
with SLE and FD complicated by APS.
The patient’s severe myocardial dysfunction, not
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being consistent with APS or other conditions, led
to the diagnosis which was conﬁrmed by testing
GLA enzyme activity (which was low, although
this is not always the case in patients) and by gen-
etic testing that revealed an unusual GLA poly-
morphism (P343L) contributing GLA enzyme
deﬁciency.32
Recently, the patient suﬀered an MI with a distal
anterior descending artery thrombus. Stroke,
thrombophilia and the presence of autoantibodies,
including ‘lupus-associated’ antibodies to dsDNA,
ENA and phospholipids,37 can be features of
patients with FD. Since the prevalence of aPL in
Fabry’s patients is up to 45%37 compared to
around 30% in lupus patients,38 it is diﬃcult
to assess whether the presence of aPL in this patient
resulted from the FD or the APS. However, it
seems likely that high levels of aPL that developed
between 2002 and 2009 may well have contributed
to the MI suﬀered in 2009.
Originally it was believed that pathology in FD
was caused by increased lipid (Gb3) deposition in
various organs. However, recent work suggests that
Gb3 is immunogenic and provides a continuous
stimulus, potentially by changing the nature of
lymphocyte cell membranes, thereby creating an
environment able to sustain autoimmune
responses.30 These observations are consistent
with what is known about defects in immune cell
function in patients with SLE.39 SLE patients are
characterized by an altered composition of lympho-
cyte cell membrane lipids, including Gb3, that can
increase their activation.39 Furthermore, increased
accumulation of glycolipids in the cell membrane of
lymphocytes increases oxidative stress and the for-
mation of reactive oxygen species, both factors that
inﬂuence the inﬂammatory response and contribute
to increased cardiovascular risk.32 Since patients
with SLE are associated with an unexplained
increased cardiovascular risk (up to 10 times overall
and up to 50 times in female patients aged between
35 to 44,12,40 there may be a case for screening cer-
tain SLE patients for Gb3 and GLA enzyme activ-
ity, for example, those with unexplained cardiac
symptoms.
Unlike the previous reports, the patient
described here was treated with agalsidase beta, a
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relatively new therapy for lysosomal storage dis-
eases.32 Enzyme-replacement therapy (ERT) (agal-
sidase alfa or agalsidase beta) is able to reduce Gb3
expression in the serum; this was the case in this
patient as shown in Figure 2 but its eﬀect on disease
symptoms can vary. Both drugs have been shown
to improve cardiac involvement in FD,41,42 which
was also the case in our patient (Figure 3).
However, as mentioned our patient did go on to
have an MI with a distal anterior descending
artery thrombus. Relevant to this, one in vitro
study reported that ERT may contribute to endo-
thelial damage, which could explain why strokes
continue to occur in patients treated with ERT.43
Conclusion
This case highlights similarities in the disease
pathogenesis between patients with SLE and FD.
The co-existence of FD and SLE may be more
common than previously believed. Furthermore,
defects in lipid biosynthesis, such as is seen in
FD, could contribute to the development of auto-
immunity. Finally, this case reminds the physician
that although lupus is a complicated disease on its
own, approximately 30% of patients also present
with a second (or more) concomitant autoimmune
disease which adds to the complication. Thus the
diagnosis of lupus is just the beginning of the story.
Final diagnosis
SLE and APS with Fabry’s disease.
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